Gretchen Hull Swim Across America – Nantucket Hometown: Nantucket, MA 10 years supporting Swim Across America Age: 49
Gretchen Hull is a triple threat supporter of Swim Across America. She’s an oncology nurse and Director of Infusion Services at Nantucket Cottage Hospital, passionate about health and personal wellness, and a swimmer!
In Gretchen’s own words, “the mission of Swim Across America – Nantucket – to support cancer services and research – aligns perfectly with my professional and personal goals.”
Gretchen has worked at Nantucket Cottage Hospital since 2002 and has been involved with Swim Across America for over a decade. It wasn’t until 2014, when Keytruda, of which Swim Across America assisted funding research, first became available at NCH, that she truly felt the impact and miracle of groundbreaking immunotherapy research.
“When Keytruda became available in 2014 there were only two chemotherapy certified nurses at NCH. I was the first nurse at my facility to administer Keytruda for its first indication. I knew it was a pivotal time in cancer care.”
Gretchen watched how the introduction of immune therapy changed the course of patient’s lives and trajectory of cancer diagnosis from terminal to chronic and curative at times. Moreover, how immunotherapy redefined how we view cancer and how cancer treatments have expanded across multiple types of cancer and benefited millions of people.
“I have to emphasize to nurses beginning their practice after the dawn of immunotherapy exactly how groundbreaking it is. I use the term “miracle” when referring to some outcomes.”
This year, Gretchen will swim the 4-mile course at Swim Across America – Nantucket.
Swim Across America has raised $100 million since its inception in 1987 to support cancer research and clinical trials across the U.S. Please contact Jeni Howard at jhoward@jhowardpr.com for media inquiries.
Swim Across America College Ambassadors are are part of the next generation of leaders. They support SAA by helping to engage the younger audience, promoting the Swim Across America mission and brand and encouraging their local communities’ involvement. Once you have been selected, we’ll reach out to congratulate you and send you an SAA College Ambassador’s Member Kit in the mail so you can show off your SAA spirit and be set up for success.
Here’s what you can expect in the mail:
1. Swim Across America Trucker Hat
Enjoy the exclusive Swim Across America College Ambassador’s Trucker Hat with our popular Wave logo. Perfect to throw on while enjoying time outside or walking to class.
2. Swim Across America Water Bottle
Stay hydrated and show your support with your new SAA branded water bottle.
3. Swim Across America Stickers & Buttons
Show your love on your car, laptop, backpack or jacket with the sticker and button we’ll be sending to help you spread the word about SAA!
4. Boost Your Fundraising Tips Sheet
Utilize these resources to help boost your fundraising and make a bigger impact!
Mass General Cancer Center Joins the Swim’s Other Beneficiaries Nantucket Cottage Hospital Oncology Program and Palliative and Supportive Care of Nantucket.
NANTUCKET, Mass., April 26, 2023 – Swim Across America Nantucket is pleased to announce that Mass General Cancer Center will join Nantucket Cottage Hospital’s Oncology Program and Palliative and Supportive Care of Nantucket as a beneficiary of the Swim Across America Nantucket Open Water Swim event. The Swim Across America Nantucket open water swim has been held each Summer since 2012 and makes waves in the fight against cancer. This year’s event will be Saturday, July 22, 2023.
In addition to continuing to support the two local beneficiaries, Mass General will provide a research component to the list of services supported by Swim Across America Nantucket’s annual fundraising event. Dr. Bryan Choi, MD, PhD, is an attending neurosurgeon in the Department of Neurosurgery and the Stephen E. and Catherine Pappas Center for Neuro-Oncology at Mass General. He specializes in surgical care for patients with benign and malignant brain tumors. During his neurosurgery residency at the Massachusetts General Hospital, he pursued a postdoctoral fellowship in the laboratory of Dr. Marcela Maus, focused on developing CAR T-cell therapies for cancer. He also leads a research laboratory with the goal of developing the next generation of cell therapies and clinical trials in neuro-oncology.
“We are very honored to have the opportunity to support Dr. Choi in his work in CAR T-cell therapies,” said Jim Pignato, co-event director of Swim Across America Nantucket. “Adding a funding arm with a research component has been something we’ve been exploring. Teaming up with Dr. Choi and Mass General Cancer Care is a natural fit.”
“Dr. Choi’s work is groundbreaking and holds the potential to shift the paradigm of treatment for an otherwise devastating disease,” said Keith Erickson, director of development at Mass General Hospital.
“Our vision is to continue to help serve the Nantucket patient, from diagnosis through treatment, while also offering this very important research component, that will help all patients, not only those on Nantucket”, said Jill Roethke, co-event director of Swim Across America Nantucket.
This announcement comes on the heels of a banner 10th year for Swim Across America Nantucket, where more than $600,000 was raised for on-island cancer services and patient care in 2022.
Swim Across America was founded in 1987 with its first open water event in Long Island Sound. Since that time, the nonprofit organization has raised more than $100 million to fight cancer. In its 36 years of “making waves to fight cancer,” more than 100,000 swimmers and 150 Olympians have swum the circumference of the earth three times, uniting a movement to fight cancer that has created a groundswell of support spanning all generations. Today, more than 24 communities hold open water swims and charity pool swims each year, from Nantucket to under the Golden Gate Bridge, which support innovative cancer research, detection and patient programs.
Swim Across America’s funding of clinical trials for patients helped contribute to four FDA approved life-saving immunotherapy cancer treatments: Yervoy, Opdivo, Tecentriq and Keytruda. More than 60 scientific grants are funded each year and there are now ten dedicated Swim Across America Labs at major institutions including: Children’s Healthcare of Atlanta, John Hopkins Medicine Baltimore, Rush University Medical Center Chicago, Baylor Scott & White Charles A. Sammons Cancer Center in Dallas, Memorial Sloan Kettering Cancer Center New York, Infusion Center at Nantucket Cottage Hospital, Adolescent and Young Adult (AYA) Lounge at the Moffitt Cancer Center in Tampa, UCSF Benioff Children’s Hospital Oakland and San Francisco, Vanderbilt-Ingram Cancer Center in Nashville, and the Seattle Cancer Care Alliance.
Since 2012, Swim Across America Nantucket has raised more than $4 million for its beneficiaries: Nantucket Cottage Hospital and Palliative and Supportive Care of Nantucket. Each year Swim Across America Nantucket is proud to host more than 400 swimmers and volunteers, spectators and supporters, as well as Olympians near and far at the charity swim. This year’s swim will take place on Saturday July 22, 2023, at Jetties Beach on the island of Nantucket.
Michelle Deaton Swim Across America – Tampa Hometown: Wesley Chapel, Florida 2 years supporting Swim Across America Age: 50
Michelle Deaton has a lot to celebrate this year and she wanted to mark the occasion by doing something she had never done before.
“I turned 50 in March and I’m five years cancer free! What better way to celebrate than with a two-mile swim with Wyatt!”
Last year, Michelle was a proud supporter of her son, Wyatt, who swam 2 miles in the 2022 Swim Across America – Tampa event. He raised nearly $6,000 in her honor. This year, they are training – and raising funds – together. What makes their swim even more special is that the event falls on Mother’s Day weekend.
“I’m so excited that my mom is training to swim with me,” said Wyatt. “She keeps telling me she will swim faster than me and beat me back to the beach. I’m just proud that she is cancer-free, just celebrated her 50th birthday on March 26, and is going to be my swim partner for Swim Across America.”
Michelle is cancer-free but that doesn’t mean she will stop supporting Swim Across America. She is likely one of our most enthusiastic participants!
“I just love, love, love Swim Across America and all it stands for,” said Michelle Deaton. “I talk about the work that Swim Across America supports everywhere I go and to everyone. I’m Swim Across America’s biggest fan. I’m thrilled to be able to swim and be a part of such a great event that impacts the lives of so many. I’m a true believer that when you put your mind to something, it might not be easy, but I’m blessed as I have gone through something tough like a cancer diagnosis, and it made me realize even more how miraculous our bodies really are.”
Swim Across America has raised $100 million since its inception in 1987 to support cancer research and clinical trials across the U.S. Please contact Jeni Howard at jhoward@jhowardpr.com for media inquiries.
Susan McPherson was no stranger to Swim Across America, but her contributions were always in honor of other family members and friends who had cancer diagnoses. After a shocking diagnosis in December 2020, the reason to support Swim Across America-Nashville now became much more personal for Susan.
“I went to the doctor because I was experiencing new-onset shortness of breath and found out I was anemic. After additional tests, the doctors told me they found a large tumor and multiple metastases in my abdomen and that I had stage four colon cancer.”
Susan’s particular genetic profile made her a candidate for immunotherapy. She began treatment at the Vanderbilt-Ingram Cancer Center, which is the beneficiary of the Swim Across America-Nashville Pool Swim.
“In fact, the type of immunotherapy I was given – Keytruda – was developed in the Swim Across America funded lab at the Johns Hopkins Cancer Center! What an incredibly serendipitous moment it was when I realized that the treatment that could help save my life was initially funded through Swim Across America fundraising events.”
Susan received treatment for two years and is now cancer-free. And her participation in this year’s Swim Across America – Nashville event is that much more poignant.
Susan’s daughter-in-law, Chris, is one of the event directors and coaches at the Ensworth Natatorium where the event is held. Her son, John, is a cardiologist at Vanderbilt University Medical Center. For the second year, Chris and John will swim with their team “Chris’ Cancer Crushers” in their endeavor to “make waves to fight cancer.”
Swim Across America has raised $100 million since its inception in 1987 to support cancer research and clinical trials across the U.S. Please contact Jeni Howard at jhoward@jhowardpr.com for media inquiries.
Owen Johnson is just 13 years old, and he already recognizes the impact funds raised at a Swim Across America charity swim have on patients and families.
“My dad, Brad Johnson, was diagnosed with stage four head and neck cancer before I was born. He survived because of new medicines discovered by cancer researchers, like the ones funded by Swim Across America.”
In 2020, the then-11-year-old swimmer had the idea to give his dad an unforgettable Christmas present. Instead of exchanging gifts, Owen set up a GoFundMe in honor of his dad’s fight against cancer. Owen raised over $2,000 and since then, has raised another $4,000 through his participation in the Swim Across America – Charleston-Kiawah events.
“I know Swim Across America gives money directly to researchers. My dad was the Event Director for Swim Across America – Charleston-Kiawah for a few years, and Swim Across America gives grants to cancer researchers at Hollings Cancer Center in Charleston where we live.”
This year, Owen and Brad will swim together at the Swim Across America – Charleston-Kiawah event on June 10. They are also celebrating a remarkable milestone. Brad has been cancer-free for 20 years.
“To celebrate 20 years and all the things my dad has accomplished since beating cancer – Ironman events, marathons, Triathlon World Championships, having a family – we are teaming up to raise $20,000 for the 2023 Swim Across America – Charleston-Kiawah event.”
“I hope that by raising money for Swim Across America, donations will help researchers get the funding they need to help more people like my dad.”
Swim Across America has raised $100 million since its inception in 1987 to support cancer research and clinical trials across the U.S. Please contact Jeni Howard at jhoward@jhowardpr.com for media inquiries.
An immunotherapy clinical trial that Swim Across America provided grant funding has reached another milestone.
The Dr. Luis Diaz Lab at Memorial Sloan Kettering began receiving grants from Swim Across America in 2017. SAA grant funding allowed Dr. Diaz and his colleague, Dr. Andrea Cercek, to meet patients and conduct immunotherapy research. With SAA grant support, the lab opened a clinical trial and recruited 14 patients with advanced rectal cancer. The patients qualified through genetic testing and were treated with a single dose of immunotherapy. The patients didn’t require surgery, chemo, or radiation–which was remarkable as traditional treatments often have a negative emotional, physical, and financial effect on the quality of life for patients and their families.
Dr. Luis Diaz and Dr. Andrea Cercek
All 14 patients responded with no evidence of disease. This is believed to be the first time a clinical trial has shown a 100% response rate. Read the full story here.
Recently, the FDA Advisory Committee supported expanding the clinical trial to more patients based on the data from the trial.
The Diaz/Cercek lab has focused on rectal cancer where standard treatment options are surgery, chemotherapy, and radiation. While these treatments might save a patient, they have significant quality-of-life effects and often present the need for ongoing care.
This trial is genetically dependent and focused on advanced rectal cancer. Dr. Diaz and Dr. Cercek envision the immunotherapy being offered to patients with other cancer types who meet the genetic profile. Proceeds from the Long Island Sound and Nassau/Suffolk – Sound to Cove charity swims continue to help fund the ongoing research and clinical trial at Memorial Sloan Kettering.
Swim Across America has a proven track record of identifying and funding early-stage ideas of promise. Swim Across America grants have played a major role in clinically developing FDA-approved immunotherapy treatments ipilimumab (YERVOY), nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), and atezolizumab (TECENTRIQ).
To date, Swim Across America has contributed close to $4.2 million for clinical research at Seattle Cancer Care Alliance and Fred Hutch. Starting in 2019, funds raised from the SAA-Seattle have gone to support breakthrough research by young investigators. In 2021, six grants were awarded to researchers focused on: lymphoma, sarcoma, breast, pancreatic, and urological cancer research. Below, the grant recipients share progress statements on their research over the last year.
Dr. Meghan Flanagan
Dr. Meghan Flanagan Research focus: Breast cancer Project title: Association of HSD3B1 (1245C) genotype with recurrence among post-menopausal women with estrogen receptor- positive, HER2- negative breast cancer Background: Endocrine (antiestrogen) therapy reduces the risk of recurrence and improves mortality among women with hormone-receptor positive breast cancer. However, approximately one-quarter of women are inherently resistant or develop resistance to endocrine therapy. Ultimately, this research may allow us to identify women with innate endocrine resistance and develop novel therapeutics and treatment strategies. Progress Statement: The SAA funds were used to evaluate whether an association exists between a mutation in a gene (HSD3B1, involved in hormone biosynthesis) and breast cancer outcomes. Using extensively collected clinical and pathologic data about patient demographics, tumor and treatment data and recurrence rates, we were able to show that women with two mutations in the HSD3B1 gene had higher rates of distant metastatic recurrence compared to those women who did not have this mutation. Future studies will be forthcoming to determine how this mutation may decrease the effectiveness of anti-estrogen medications that are used universally in post-menopausal ER+ breast cancer. This mutation is found in up to 15 percent of ER+ post-menopausal breast cancer patients, and if shown to decrease the effectiveness of anti-estrogen medications, there would be potential indications for alternative treatment strategies in these patients.
Dr. Sita Kugel
Dr. Sita Kugel Research focus: Pancreatic Cancer Project title: Exploring novel functions of HMGA2 in pancreatic cancer Background: Pancreatic Ductal Adenocarcinoma (PDA) is an extremely lethal disease with a 5-year survival rate of less than 10%. Recent work has led to the discovery that PDA can be subdivided into two principal subtypes based on transcriptional signatures: classical and quasi-mesenchymal (QM). The QM PDA subtype is more aggressive and has the worst overall survival. Our laboratory has been focused on understanding of the mechanisms that drive each subtype in hopes of identifying therapeutic vulnerabilities that may be exploited in the clinic. Progress Statement: Within an already challenging malignancy, there are transcriptional subtypes of pancreatic ductal adenocarcinoma that are especially lethal. Understanding what defines each subtype, as well as their susceptibilities and mechanisms of resistance, will help to identify new targeted therapies or combination therapies and lead to more treatment options for this devastating disease.
Dr. Jonathan Sham
Dr. Jonathan Sham Research focus: Pancreatic Cancer Project title: Novel Drug- eluting Biopolymer to Reduce Pancreatic Fistula and Improve Outcomes After Pancreatic Surgery Background: Pancreatectomy is the mainstay of any potentially curative treatment regimen for pancreatic cancer. Despite an overall improvement in the safety of pancreatic surgery over the past several decades, the morbidity of pancreatectomy remains exceedingly high. The most significant complication after pancreatic surgery is postoperative pancreatic fistula (POPF), which occurs in up to 60% of cases. The use of a biopolymer, poly(Nisopropylacrylamide) (PNIPAM), is an innovative method to prevent leakage of pancreatic juice from the cut surface of the gland, while the suspended octreotide- eluting microspheres will simultaneously reduce baseline pancreatic fluid secretion. This novel dual-action approach will be tested in a validated rat model of POPF with the goal of rapid clinical translation and patient benefit. Progress Statement: Swim Across America is advancing our work to improve outcomes after pancreatic surgery. Their support is enabling a trailblazing collaboration between surgeons and bioengineers to develop novel ways to stop leaks after pancreas surgery and make patients live happier, healthier and longer lives. Polymer synthesis is moving forward, and two teams are working on creating and testing polymers with different characteristics for use in our animal experiments.
Dr. Jordan Gauthier
Dr. Jordan Gauthier Research focus: CAR T-cell therapy Project title: Factors associated with failure of CD19 CAR T cells in diffuse large B cell lymphoma Background: We are investigating two factors potentially critical to failure of CD19 CAR T-cell therapy for DLBCL: a) T cell dysfunction, impeding the generation of functional CAR T cells during manufacturing; b) the suppressive tumor microenvironment (TME). Our studies will better characterize T cell dysfunction and the TME as core mechanisms of failure of CD19 CAR T cells and identify potential targets to improve outcomes of CAR T-cell therapy for DLBCL. Progress Statement: The Swim Across America grant allowed us to explore the two following aims. Aim 1: To determine whether exhausted T cells are associated with treatment failure after CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL). We analyzed blood samples from 34 DLBCL patients treated on a clinical trial of CAR T-cell therapy. While we did not confirm an association between exhausted T cells and treatment failure, we found that a higher proportion of terminally differentiated T cells may have an adverse impact on the outcomes of CAR T-cell therapy. Aim 2: To determine if an exhausted gene signature in T cells from lymphoma tumors is associated with treatment failure, we analyzed pre-treatment tumor biopsies obtained from 17 patients receiving CAR T-cell therapy. In biopsies from patients in complete response after CAR T-cell therapy, we found that T cell-associated genes were overexpressed compared to patients not in complete response after treatment. This suggests that tumors more permissive to T cell infiltration might respond better to CAR T-cell therapy. So far, we have not confirmed that an exhausted gene signature is associated with treatment failure. The SAA grant has been used to design and optimize novel assays that will allow us to further address this aim in the future.
Dr. John Lee
Dr. John Lee Research focus:Sarcoma Project title: Development of STEAP1 chimeric antigen receptor T-cell therapy for Ewing sarcoma Background: Ewing sarcoma (ES) is a soft tissue/bone cancer with 200 newly diagnosed adolescents/young adults per year in the United States. Patients with metastatic dissemination face a very grim prognosis as available treatments are unable to eradicate the disease. New therapeutic approaches are needed. If successful, these studies will help lay the groundwork for the development and clinical translation of a first-in-field STEAP1 CAR T-cell immunotherapy for ES. Progress Statement: We applied the Swim Across America grant to evaluate whether a novel chimeric antigen receptor (CAR) T cell therapy targeting the protein STEAP1 could be an effective strategy to treat Ewing sarcoma. Our results indicate that human Ewing sarcoma tumor models commonly express STEAP1 and are susceptible to killing by STEAP1 CAR T cells. In related studies, we have also determined that STEAP1 CAR T cell therapy appears safe in a novel mouse model that we engineered to express human STEAP1. Together, these findings provide the rational to translate STEAP1 CAR T cell therapy into clinical trials for Ewing sarcoma in the near future.
Dr. Adam Gadzinski
Dr. Adam Gadzinski Research focus:Urological cancer Project title: Interstate Telehealth to improve access to urological cancer care among rural patients. Background: Timely access to urological cancer care is challenging for rural patients who often travel great distances to tertiary centers. This is particularly true for patients residing in the WWAMI (Washington, Wyoming, Alaska, Montana, Idaho) region. We hypothesize that Telehealth will provide similar patient satisfaction, reduced costs, and earlier time to treatment. We further hypothesize that implementation of the interstate Telehealth program will decrease referral to visit time and increase clinical efficiency. Lastly, we hypothesize that providing Telehealth appointments will increase the frequency of referrals from rural areas. We anticipate that implementation of our interstate Telehealth program will improve access to urological cancer care for rural and underserved patients throughout the WWAMI region. Progress Statement: Our SAA grant has been used to support our telemedicine research efforts to assess the quality of telemedicine visits for cancer patients from rural areas and the Pacific Northwest states. We have demonstrated that telemedicine visits save cancer patients and their families a significant amount of time and money that would have been spent traveling to doctor appointments. We also found that patients are very satisfied with receiving cancer care remotely via telemedicine, especially during the COVID-19 pandemic.
With the support of Swim Across America grant funding, researchers at Rush University Medical Center are gaining momentum in their quest to discover the early detection tools and treatment options of the future in the fight against cancer. RUSH’s experts intimately understand the physical, emotional and financial burdens of cancer on patients’ lives, and they refuse to let the disease rest as the second leading cause of death in the U.S. Since 2012, Swim Across America–Chicago has awarded More than $2M that has funded these early stage research projects.
Dr. Carl Maki
Grant Recipient: Carl Maki, PhD Professor in the Department of Anatomy & Cell Biology at Rush Medical College
Project: Targeting proteins to improve drug responses for patients with treatment-resistant breast and lung cancers
Project Details: By studying cancer at the molecular level, Maki and his team have made significant strides in identifying promising new options for treatment-resistant breast and lung cancers.
In 2015 Maki received an SAA grant to study a family of enzymes known as prolyl peptidases (which regulate blood pressure and appetite) as a possible mechanism to help prevent or alleviate resistance to the drug tamoxifen, one of the most widely used therapies for the 80% of women with breast cancer whose tumors are considered estrogen receptor-positive. Maki and his team found that an enzyme inhibitor for prolyl peptidases, used in conjunction with tamoxifen, effectively killed breast cancer cells in rodents. Using these promising findings, Maki applied for and received a prestigious R01 research award for continued study from the National Institutes of Health and a grant from the Department of Defense to extend this research into triple-negative breast cancer.
In 2020 Maki was awarded another SAA grant to study proteins called histone demethylases in non-small cell lung cancer. Among the deadliest of all cancers, this accounts for about 4 in 5 lung cancer cases. Maki and his colleagues are studying how these proteins may allow lung cancer cells to resist the drugs currently used to treat the disease. By blocking these proteins, the team has been able to kill lung cancer cells in laboratory studies and lung tumors in mice. They identified a novel mechanism for how these inhibitors improve treatment outcomes and recently published their results.
“What starts out as an idea might result in something great,” Maki said. “SAA gives less established researchers a chance and helps all researchers fund pilot projects that ultimately can lead to bigger things.”
Dr. Animesh Barua
Grant Recipient: Animesh Barua, PhD Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College Director of the Proteomics Core and MicroRNA and Gene Expression Core
Project: Seeking an improved early detection test for ovarian cancer
Project Details: Throughout his career, Barua has relentlessly pursued the development of an effective early detection test for ovarian cancer. With an SAA grant received in 2020, he and his team are drawing upon extensive experience with immunoassays and ultrasound imaging of ovarian tumors to take the next steps forward in this important area of research. In this study, Barua’s lab is developing a fresh approach to early detection testing involving the fimbriae (fingerlike protein branches that guide an egg during ovulation) of the fallopian tubes. Emerging information shows that high-grade serous carcinoma — the most malignant and most common type of ovarian cancer — originates from the fimbriae. The aims of Barua’s study include identifying specific protein markers associated with cancer development in the fimbriae and determining the efficacy of these markers in predicting cancer growth.
Dr. Amanda Marzo
Grant Recipient: Amanda Marzo, PhD Assistant Professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College
Project: Bolstering the body’s natural immune response for greater success in the battle against breast cancer
Project Details: Tumor-infiltrating CD8 T-cells are essential for tumor immunity. However, many of these cells become exhausted and are unable to protect against tumor growth. Key molecules known as checkpoint inhibitors, such as programmed death-ligand 1 (PD-L1) expressed on tumor cells and programmed cell death protein 1 (PD-1) expressed on CD8 T-cells, have been shown to be a hallmark of CD8 T-cell exhaustion. For most tumors, blocking PD-1/PD-L1 signaling does not result in tumor rejection. A main cause for the ineffectiveness of checkpoint blockade immunotherapy lies in the dysfunctional state of CD8 T-cells once they enter the tumor. CD8 T-cells are specialized in killing tumor cells but face multiple suppressive signals that dampen their ability to effectively respond. Using an SAA grant received in 2019,Marzo and her colleagues seek to improve scientists’ understanding of how other immune-modulating treatments can improve CD8 T-cell responsiveness to checkpoint inhibitors. Specifically, the researchers aim to determine if metformin, an anti-diabetic drug, could enhance tumor-infiltrating CD8 T-cell responsiveness to PD-1 blockade therapy by altering breast cancer metabolism. The team also seeks to establish if bolstering the number of infiltrating CD8 T-cells into the tumor using interleukin-15 complexes (known to cause proliferation of cells and increase their killing ability) in combination with PD-1 blockade therapy could induce regression of established breast tumors and lead to long-term tumor immunity. Marzo and her team plan to publish the results of their study and are using preliminary data generated from this research to apply for a federal R21 grant.
Dr. Alan Blank
Grant Recipients: Alan T. Blank, MD, MS Assistant Professor in the Department of Orthopedic Surgery, Section of Orthopedic Oncology at Rush Medical College
Jitesh Pratap, PhD Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College
Dr. Jitesh Pratap
Project: Pursuing therapeutic approaches to prevent breast cancers from
metastasizing to the bones
Project Details: In this study funded by a 2019 SAA grant, Blank and Pratap seek to fulfill a need for the development of a therapy that can prevent primary breast cancers from metastasizing to the bones and surviving there. The researchers hypothesize, based on results of previous studies, that a subgroup of patients with breast cancer that has metastasized to the bone has high levels of autophagy (a process of recycling of cellular components), Runx2 proteins and acetylated α-tubulin — worsening their chances of survival. To investigate this, the researchers are working to determine the clinicopathologic association with the autophagy pathway in tumor samples from patients with cancer that has metastasized to the bone. They are also creating patient-derived xenograft models of bone metastasis. Blank and Pratap hope the results of this study will propel the development of better combinatorial therapeutic approaches to treat bone metastasis.
Dr. Faraz Bishehsari
Grant Recipient: Faraz Bishehsari, MD, PhD Associate Professor of Medicine & the Graduate College in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Section of Gastroenterology at Rush Medical College Associate Director for Molecular & Translational Research for the Rush Center for Integrated Microbiome & Chronobiology Research
Project: Pursuing precision medicine to improve outcomes for pancreatic cancer patients
Project Details: Patients with pancreatic ductal adenocarcinoma — the most common form of pancreatic cancer — face poor survival rates, with only 6%-8% of patients surviving five years after diagnosis. This cancer does not respond well to targeted therapies. Bishehsari and his colleagues received an SAA grant in 2019 to establish a platform towards precision medicine in order to tailor therapies based on patients’ individual tumor characteristics. The researchers have developed primary cancer cells from a small tissue sample obtained during diagnostic pancreatic biopsies from pancreatic ductal adenocarcinomas. Molecular profiling of these patient-derived tumor organoids explained the variation in response to a variety of conventional and investigational therapies. They are optimizing this platform to help eventually establish individualized treatments for pancreatic cancer patients.
Dr. Jeff Borgia
Grant Recipient: Jeffrey A. Borgia, PhD Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College Director of the Rush University Cancer Center Biorepository and Rush Biomarker Development Core
Project: Identifying biomarkers for the improved evaluation and treatment of stage I non-small cell lung cancer
Project Details: Lung cancer is the leading cause of cancer-related mortality in the United States, but evidence is surfacing that widespread lung cancer screening programs may improve patient outcomes when the disease is detected early. Borgia and his team received an SAA grant in 2020 to develop a new diagnostic method to improve physicians’ ability to predict the recurrence of stage I non-small cell lung cancer, or NSCLC. This would help physicians identify patients who would benefit from adjuvant treatment options or closer surveillance. The aims of this study include identifying biomarkers for disease recurrence in stage I NSCLC patients and evaluating these biomarkers for their value in predicting recurrence.
Swim Across America has supported cancer research at Rush University Medical Center since 2012 through more than $2 million in grant funding. Together, Swim Across America and RUSH are relentlessly fighting cancer, working to save lives.
June 9, 2022—The New England Journal of Medicine published a paper on June 5 that 12 patients completed a phase 2 clinical trial for advanced rectal cancer and showed a 100% clinical complete response to dostarlimab, an immunotherapy treatment produced by GlaxoSmithKline. The clinical trial was conducted at Memorial Sloan Kettering with early-stage grant funding from Swim Across America.
Reviews of the clinical trial and quotes in the New York Times from cancer experts are hopeful:
“I believe this (a 100% response) is the first time this has happened in the history of cancer,” commented Dr. Luis Diaz, an author of the New England Journal of Medicine paper.
Dr. Luis Diaz, Memorial Sloan Kettering
“There were a lot of happy tears,” said Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and a co-author of the paper.
Depending on patient size and other factors, the cost to run a clinical trial can run into millions of dollars. Early-stage sponsors such as Swim Across America are necessary to fund the costs. Swim Across America’s grant for the MSK clinical trial helped fund the science and speed of sharing of information. Other funding partners of the MSK clinical trial are the Simon and Eve Colin Foundation, GlaxoSmithKline, Stand Up to Cancer, and the National Cancer Institute. Swim Across America is delighted with the results and continues to provide grant support.
Swim Across America.
Swim Across America’s grant agreement with beneficiaries such as Memorial Sloan Kettering requires that 100% of an SAA grant must be spent on approved research and clinical trial programs. In 35-years, SAA has granted nearly $100M to innovative and otherwise unfunded ideas so that the time of oncologists such as Dr. Cercek and Dr. Diaz is protected to make progress and develop new treatments.
Swim Across America has a proven track record of identifying and funding early-stage ideas of promise. Swim Across America grants have played a major role in clinically developing FDA-approved immunotherapy treatments ipilimumab (YERVOY), nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), and atezolizumab (TECENTRIQ).
You can volunteer or swim by visiting swimacrossamerica.org/communities
Swim Across America 